Provider review
Remedy Meds Review: Results and Warranty
Remedy’s prominent results and refund promise deserve a close read. Its member outcomes are self-reported, and the weight-loss warranty requires a full year of qualifying participation.
Some links on this site are affiliate links, and we may earn a commission. How we’re paid
Visit Remedy MedsOf Remedy Meds’s 1 dated product claim documented below, 0 are consistent with the cited evidence. Comparable upfront pricing is not established here. A matching claim does not mean the compounded product was tested or FDA-approved.
Remedy may suit someone who values ongoing clinician access, but its results headline should not be treated as a personal forecast. The warranty is meaningful only if its full-year conditions fit the clinical plan.
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Compounded
Phase 3 trials
Not confirmed
September 2025
Provenance
Products reviewed at Remedy Meds
These evidence cards classify the treatments evaluated in this review. Confirm the exact medicine and formulation proposed for your prescription with the care team.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Compounded semaglutide injection
Evidence
Has the molecule been tested for what it is sold for?
Each row summarizes human evidence for the molecule and the use being advertised. Results apply to the product, dose, population and outcome studied; they do not establish that this provider’s preparation or program produces the same results. Compounded drugs are not FDA-approved. Evidence for one use should not be assumed to support another.
1
Products with human evidence
For the advertised use, out of 1 product reviewed here. The evidence concerns the molecule, not Remedy Meds's service.
1
Registry records cited
Distinct ClinicalTrials.gov records cited across the reviewed products. Registration alone does not establish that a treatment works.
The comparison
What they claim, against what the trials show
Each claim below is quoted word for word from Remedy Meds’s own page. Tap a row to see the quote, the trials behind it, and why it got that verdict.
Compounded semaglutide injectionSemaglutide · Compounded (503A)Claim reaches past the trials
“Remedy members lose 45 lbs in their first 6 months”
Read on the Remedy Meds site, October 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Registry read October 13, 2026. This study supports the molecule and studied injection, not this provider’s compounded formulation.
This is a provider-reported outcome, not a result established by STEP 1. The homepage identifies self-reported member weights; it does not make this figure a randomized comparison or a prediction for a new patient.2
Dispensing chain
Who actually fills your prescription
Read the full account
The cited public offer does not identify the dispensing pharmacy for a particular patient. Ask for that pharmacy before the order is fulfilled.
Read on the Remedy Meds site, October 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Not established in this source review
Certificate of analysis readable
A readable lot report was not verified here
Read the full testing account
No batch report was assessed in the cited treatment-page review. This does not establish that the pharmacy does not test; request the report matching the dispensed lot.
Read on the Remedy Meds site, October 2026.
Licensing
Licensed to dispense, and where
Coverage
Confirm treatment availability for your state
Read the full licensing claim
A public treatment listing does not establish eligibility for every state or every patient. Confirm the clinician and dispensing pharmacy for your location.
Read on the Remedy Meds site, October 2026.
Regulatory
The FDA warning letter
Issued September 2025
Remedy Meds — 716830. Concerns marketing and labeling.
Read the full allegation
FDA called the compounded-drug claims “false or misleading” because they implied the products were the same as FDA-approved products.
What has changed since
The current homepage identifies compounded medication and says FDA has not evaluated it. This review does not determine formal resolution of the letter.
Assessment
What holds up, and what does not
- The homepage identifies its outcomes as self-reported member data.
- Warranty conditions are available in public terms.
- Current copy distinguishes compounded products from FDA evaluation.
- Member outcome headlines do not establish a result for a new patient.
- The warranty excludes brand-name medication and microdosing.
- The guarantee requires uninterrupted qualifying participation; it is not an early exit refund.
Verdict
The bottom line
Read the warranty before assigning it value, and ask the clinician what is realistic for you. A reimbursement promise cannot substitute for evidence about your prescription.
Opens Remedy Meds' website. A link is not a recommendation to take anything.
Read the results as member reporting
Remedy describes compounded semaglutide and tirzepatide alongside clinician-led care. The striking figures on its homepage come with a disclosure that weights were self-reported by members during intake and follow-ups. That is useful context: these are service data, not a randomized trial assigning comparable people to Remedy or another provider. 1
A prospective patient needs the denominator as well as the headline. How many people remained under observation? Were early discontinuations included? Were the same treatment duration and starting characteristics used in the comparison? Those questions determine how much a reported average can tell someone deciding whether to enroll. Testimonials can describe a person’s experience without answering those questions.
Full analysis — 4 more sectionsThe ingredient has evidence; the service claim is separate · The warranty is a year-long condition, not a trial period · Put the FDA letter in its proper category · Who this fits
The ingredient has evidence; the service claim is separate
The semaglutide weight-management trial establishes that the studied injection can improve weight outcomes in its trial population. It does not validate a six-month pounds-lost promise for every customer of a telehealth service. Baseline weight, treatment duration, formulation and follow-up all affect how a result should be interpreted. 2
FDA also distinguishes a compounded preparation from an approved finished drug. Its general guidance does not determine whether a particular patient should receive this service; it explains why an approved-product result should not simply be relabeled as proof of every compounded preparation. 3
The warranty is a year-long condition, not a trial period
The June 2026 terms require twelve consecutive months of qualifying enrollment and prescribed treatment. They exclude brand-name GLP-1s and microdosing, require thirteen shipments on the stated 28-day schedule, and set a deadline for a claim after the thirteenth shipment. The goal-weight and documentation conditions also matter. This is not a prorated refund for leaving early. 4
Those restrictions create a practical question before enrollment: what happens if your clinician recommends a different treatment? Health decisions should follow clinical need. Do not continue a poorly tolerated or inappropriate plan to preserve a commercial benefit. Ask support how a medically necessary change affects the warranty, and retain the answer with the terms that applied when you enrolled.
Put the FDA letter in its proper category
FDA’s September 2025 letter addressed marketing that implied compounded products were the same as approved products. The cited findings concern misleading claims; they do not establish contamination or a defective batch. The current homepage carries an FDA-evaluation distinction, but that observation alone cannot establish formal closure of the warning letter. 5
For the individual order, identify the prescribing professional, the pharmacy and the precise formulation. Ask who will answer a question after delivery and how to report a product concern. These are more useful purchasing questions than deciding whether a provider is wholly good or bad based on a single headline or regulatory document.
Who this fits
Consider Remedy if you want ongoing care and can evaluate the full proposed commitment before paying. Be cautious if the main attraction is the expectation of a guaranteed number of pounds lost or the belief that the warranty lets you leave at any time with all money returned. The public evidence and contract do not support those readings.
Questions
Frequently asked questions
Is the results headline a randomized clinical-trial finding?
No. Remedy identifies its member outcomes as self-reported service data. Those data do not establish what an individual new patient will lose.
Does the warranty cover brand-name treatment?
The reviewed terms exclude brand-name GLP-1 medication and microdosing. Other eligibility and documentation conditions also apply.
Does the FDA letter mean contaminated medication?
No. The cited letter concerns misleading marketing about compounded products and FDA-approved products. It does not establish contamination.
Compare
Others selling what Remedy Meds sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Ranked
The lists Remedy Meds is on
Method
How we checked this
Non-product facts last checked October 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Remedy Meds's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 5 sources
- Remedy Meds (2026). Current public treatment offer. Remedy Meds; accessed October 13, 2026. the Remedy Meds site
- Wilding JPH et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. Wilding JPH et al.; accessed October 13, 2026. https://pubmed.ncbi.nlm.nih.gov/33567185/
- FDA (2026). Concerns with unapproved GLP-1 drugs. FDA; accessed October 13, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- Remedy Meds (2026). Terms of service and weight-loss warranty. Remedy Meds; accessed October 13, 2026. the Remedy Meds site
- FDA (2025). Warning letter to Remedy Meds, MARCS-CMS 716830. FDA; accessed October 13, 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/remedy-meds-716830-09092025
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.